Fabricating Highly Open Porous Microspheres (HOPMs) via Microfluidic Technology
May 16th, 2022
2.9K views
The present protocol describes the fabrication of poly(lactic-co-glycolic acid)-based highly open porous microspheres (HOPMs) via the single-emulsion formulation based facile microfluidic technology. These microspheres have potential applications in tissue engineering and drug screening.
Overview
This protocol outlines the fabrication of poly(lactic-co-glycolic acid) (PLGA)-based highly open porous microspheres (HOPMs) using a microfluidic technology. These microspheres are designed for applications in tissue engineering and drug screening, providing advantages such as improved cell retention and minimal invasiveness.
Key Study Components
Area of Science
- Tissue Engineering
- Drug Screening
- Microfluidics
Background
- PLGA is a biodegradable polymer widely used in biomedical applications.
- Highly open porous microspheres facilitate cell packaging and retention.
- Microfluidic technology allows for precise control over microsphere fabrication.
- These microspheres can support complex 3D tumor models for drug testing.
Purpose of Study
- To develop a method for creating PLGA-based HOPMs.
- To enhance cell retention and minimize invasiveness in tissue engineering.
- To provide a platform for drug screening applications.
Methods Used
- Construction of a co-flow microfluidic generator using PVC tubing and a glass capillary.
- Utilization of a 26 gauge dispensing needle for microsphere formation.
- Characterization of microsphere size and porosity.
- Demonstration of the procedure by a doctoral student in the laboratory.
Main Results
- The microspheres exhibited a particle size of approximately 400 micrometers.
- Open pores were around 50 micrometers, facilitating cell retention.
- Interconnecting windows in the microspheres improved efficacy for cell retention.
- The method is straightforward and can be assembled with common materials.
Conclusions
- PLGA-based HOPMs are promising for tissue engineering and drug screening.
- The microfluidic approach is efficient and accessible for researchers.
- These microspheres can potentially enhance the development of 3D tissue models.
Frequently Asked Questions
What are PLGA-based microspheres used for?
They are used in tissue engineering and drug screening applications.
How are the microspheres fabricated?
Using a microfluidic device constructed from PVC tubing and a glass capillary.
What is the size of the microspheres?
The microspheres have a particle size of approximately 400 micrometers.
What advantages do these microspheres offer?
They provide improved cell retention and minimal invasiveness.
Who demonstrates the procedure in the video?
The procedure is demonstrated by Sheng-Chang Luo, a doctoral student.
What is the significance of the open pores?
Open pores enhance cell retention efficacy within the microspheres.
Executive Industry Relevance
Highly open porous microspheres (HOPMs) fabricated via microfluidic technology enable the creation of advanced 3D cell delivery and tissue models, supporting predictive drug screening and regenerative medicine research. Their injectable, modular format improves cell retention and viability, addressing key challenges in translational model development and preclinical assay fidelity. This platform supports scalable, reproducible workflows for biopharma teams seeking to de-risk early discovery and accelerate portfolio progression.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Facilitates construction of intricate 3D tumor and tissue models for mechanistic studies.
- Enables functional validation of cell-matrix interactions in disease-relevant systems.
- Supports predictive confidence in target engagement and biological response.
Screening & Assay Development
- Provides standardized, reproducible microcarrier platforms for high-content drug screening.
- Enhances assay scalability and quantitative output through uniform microsphere size and porosity.
- Improves screening readiness by supporting robust cell viability and distribution.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by enabling physiologically relevant cell delivery.
- Maintains continuity from discovery through preclinical validation with modular, injectable carriers.
- Reduces risk of late-stage biological failure by improving in vitro to in vivo model fidelity.
Pipeline & Workflow Integration
HOPMs integrate into the discovery-to-preclinical continuum as a modular platform for cell encapsulation, 3D model construction, and drug screening.
- Discovery Biology: Supports hypothesis testing and pathway clarification in complex tissue environments.
- Screening: Delivers reproducible, quantitative readouts for compound evaluation in 3D systems.
- Analytics: Enables measurement of cell viability, retention, and distribution within standardized carriers.
- Translational Research: Bridges in vitro and in vivo studies by supporting injectable, minimally invasive delivery.
- Enterprise Reuse: Offers a reusable microfluidic fabrication capability adaptable to diverse cell types and biochemical cues.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in early-stage models.
- Operational Value: Standardizes fabrication and assay conditions for reproducibility and scalability.
- Strategic Value: Enables better go/no-go decisions and capital efficiency by improving model relevance.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of discovery programs.
Implementation Considerations
- Requires expertise in microfluidic device assembly and emulsion processing.
- Needs access to ultrasonic emulsification and lyophilization infrastructure.
- Demands cross-team standardization of formulation and processing parameters.
- Adaptable to various cell types and biochemical encapsulants as supported by the protocol.
- Dependent on precise control of flow rates, emulsifying power, and temperature for reproducibility.
Biopharma FAQs
Why does null hypothesis testing matter for 3D tumor model validation?
Null hypothesis testing ensures that observed effects in drug screening using HOPMs are statistically significant and not due to random variation. This increases confidence in target validation and supports robust decision-making in early discovery. Reliable statistical analysis underpins the predictive value of 3D model outputs.
How does independent variable isolation fit the microfluidic fabrication workflow?
Isolating variables such as PLGA concentration, porogen content, and emulsifying power allows teams to systematically optimize microsphere properties. This controlled approach supports reproducibility and enables mechanistic de-risking in model development. It also facilitates cross-study comparisons and process standardization.
What do quantitative dependent variable measurements enable in cell retention assays?
Quantitative measurements of cell viability, adhesion, and distribution within HOPMs provide actionable data for screening and model optimization. These outputs enable teams to compare formulations and assess the impact of microsphere architecture on biological outcomes. Such data are critical for advancing candidates through the discovery pipeline.
Why are replication requirements important for cross-functional collaboration in HOPM production?
Replication ensures that HOPM fabrication and cell encapsulation protocols yield consistent results across teams and sites. This supports reliable data generation, facilitates technology transfer, and underpins collaborative assay development. Standardized replication reduces operational risk and accelerates portfolio progression.
What statistical analysis capabilities are required before implementing HOPM-based screening?
Teams must establish statistical methods to analyze cell viability, retention, and distribution data from HOPM-based assays. Robust analysis enables detection of significant differences between conditions and supports data-driven decision-making. These capabilities are essential for validating assay performance and ensuring translational relevance.
